Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand ...

Cancer drug demand drives higher sales for AstraZeneca - Revenues from oncology products made up 43% of the company’s total ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...